At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
famciclovirdrug
Likely dose
famciclovir 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections
In Brief
A Phase 2 clinical trial evaluating famciclovir for Herpes Simplex. Completed, enrolled 18 participants across 6 sites.
Detailed Summary
This study will evaluate the acceptability and safety of famciclovir in infants with herpes simplex infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Simplex
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartOct 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedMar 16, 2007
Enrollment StartOct 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.3 years ago
Interventions
famciclovirdrug
Administered orally as a single individualized dose between 25-200 mg based on body weight.